Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Dave Baker who wrote (575)	2/18/1998 10:33:00 AM
From: E. Graphs	Respond to of 834

TXB Reports Fourth Quarter Results biz.yahoo.com

To: Dave Baker who wrote (575)	2/18/1998 9:55:00 PM
From: Bill Wexler	Read Replies (3) \| Respond to of 834

TXB continues to disappoint investors. TXB closed down on another terrible report. TXB's recent "earnings" report reflect what the company is most proficient at - selling stock. Even if TXB finally manages to get one of their drug candidates off the ground (and past experience leads us to believe this is unlikely), the rate of stock dilution will make it difficult if not impossible for the small investor to realize any profit on this grossly overvalued stock. I initially recommended shorting this stock between 5 and 6 a share. I strongly recommend continuing to short TXB and expect it to fall below 4 a share.